Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy

Rhea-AI Summary

Therapeutic Solutions International (OTC Markets: TSOI) announced new findings on April 26, 2021, showcasing a synergy between its StemVacs-V iPSC derived immunotherapy and low-dose cyclophosphamide. In animal studies, this combination led to significant tumor reductions in lung, brain, and skin cancers, alongside increased immune cell infiltration. The results indicate that lower chemotherapy doses can retain efficacy, marking a potential breakthrough in cancer treatment. Company executives highlighted the importance of this synergy for advancing cancer therapeutics and improving patient outcomes.

Positive

• Demonstrated significant tumor regression in lung, brain, and skin cancers using low-dose cyclophosphamide with StemVacs-V iPSC.
• Increased immune cell infiltration associated with tumor reduction, indicating enhanced immune response.
• Potential reduction in chemotherapy toxicity while maintaining treatment efficacy, offering a market-changing approach.

Negative

• None.

ELK CITY, Idaho, April 26, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating an unexpected synergy between its inducible pluripotent stem cell (StemVacs-V iPSC) derived immunotherapy product with low dose cyclophosphamide in evoking potent immune mediated cancer regression. 

In a series of experiments, the Company demonstrated that its previously announced stem cell derived tumor endothelial-like cell vaccine¹ enabled non-toxic doses of cyclophosphamide, an established chemotherapeutic agent, to induce significant reduction of established lung cancers, brain cancers, and skin cancers in animal models.  Furthermore, it was demonstrated that reduction of tumors was associated with increased infiltration of immune cells.

"Previous companies, such as Batu Biologics, have demonstrated the clinical safety of using the immune system to selectively kill the blood vessels that feed cancer², which was validated by FDA clearance³ to initiate clinical trials," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "As a physician who sees firsthand the suffering of cancer patients caused by current chemotherapy protocols, the thought of leveraging the patient's own immune system to allow for increased efficacy with reduced toxicity is extremely exciting."

"From a business perspective, one of the significant hurdles preventing advancement in cancer therapeutics is lack of interdisciplinary collaboration," said Famela Ramos, Vice President of Business Development. "The demonstration that our immunotherapy possesses ability to potentiate anticancer activities of existing therapeutics, thus allowing for utilization of lower doses while retaining efficacy, is a game changer in my opinion."

"The idea that killing tumor blood vessels weakens cancer, and thus allows for lower doses of chemotherapy to be effective is very attractive.  This concept has been validated in clinical trials which involved combinations of chemotherapy with the antiangiogenic activities of the monoclonal antibody drug Avastin," said Timothy Dixon, President and CEO of the Company. "Based on side-to-side comparisons, our stem cell based immunotherapy appears substantially more efficacious in inducing immune mediated "choking" of the tumor blood supply and demands deeper investigation."   

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

¹ Therapeutic Solutions International Demonstrates Potent and Selective Destruction of Tumor Blood Vessels by Leveraging Pre-Existing Natural Anti-Xenogeneic Antibodies (prnewswire.com)² Safety of targeting tumor endothelial cell antigens | Journal of Translational Medicine | Full Text (biomedcentral.com)
³ Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels That Feed Cancer | BioSpace

ir@tsoimail.com

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-regression-of-established-tumors-by-combining-its-cancer-blood-vessel-targeting-immunotherapy-with-low-dose-chemotherapy-301276645.html

SOURCE Therapeutic Solutions International

FAQ

What recent findings did Therapeutic Solutions International (TSOI) announce regarding cancer treatment?

On April 26, 2021, TSOI announced data showing that its StemVacs-V iPSC derived immunotherapy combined with low-dose cyclophosphamide significantly reduced tumors in animal models.

How does the combination of TSOI's immunotherapy and cyclophosphamide work?

The combination utilizes low doses of cyclophosphamide, an established chemotherapy drug, to enhance the immune response against tumors, leading to substantial tumor regression.

What types of cancers were studied in TSOI's recent experiments?

The studies focused on lung, brain, and skin cancers, demonstrating the effectiveness of the treatment across these types.

What benefits does TSOI's immunotherapy offer compared to traditional chemotherapy?

The immunotherapy allows for lower chemotherapy doses, potentially reducing side effects while maintaining efficacy in cancer treatment.

How might TSOI's findings impact cancer therapeutics?

The findings suggest a new approach that could enhance cancer treatment strategies, allowing for more effective and less toxic therapies.